Drug Trial Radar · NCT07187895
Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis
Last checked: Nov 19, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
17
Actual
Start
Dec 19, 2024
Primary completion
Mar 5, 2025
Study completion Mar 5, 2025
Sponsor
- Lead sponsor
- Sinotau Pharmaceutical GroupIndustry
- Sponsor type
- Industry
- First posted
- Sep 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Compare the diagnostic certainty of MIBI SPECT myocardial perfusion imaging (MPI) and XTR004 PET MPI.
Conditions
- Myocardial Perfusion Imaging
- Diagnostic Certainty
- Stable Coronary Artery Disease
Interventions
XTR004Drug
At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of vessel-level diagnostic certainty for XTR004 PET/MIBI SPECT myocardial perfusion imaging.Time frame: Day1-7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fuwai Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.